Your browser doesn't support javascript.
loading
Comparative Safety Profiles of Sedatives Commonly Used in Clinical Practice: A 10-Year Nationwide Pharmacovigilance Study in Korea.
Choi, Yeo-Jin; Yang, Seung-Won; Kwack, Won-Gun; Lee, Jun-Kyu; Lee, Tae-Hee; Jang, Jae-Yong; Chung, Eun-Kyoung.
Afiliação
  • Choi YJ; Department of Clinical Pharmacy, Graduate School of Clinical Pharmacy, CHA University, Seongnam 13488, Korea.
  • Yang SW; Department of Pharmacy and Yonsei Institute of Pharmaceutical Sciences, College of Pharmacy, Yonsei University, Incheon 21983, Korea.
  • Kwack WG; Division of Pulmonary, Allergy and Critical Care Medicine, Kyung Hee University Hospital, Seoul 02447, Korea.
  • Lee JK; Department of Internal Medicine, Dongguk University Ilsan Hospital, Goyang 10326, Korea.
  • Lee TH; Institute for Digestive Research, Soonchunhyang University Seoul Hospital, Seoul 04401, Korea.
  • Jang JY; Department of Internal Medicine, Kyung Hee University College of Medicine, Seoul 02447, Korea.
  • Chung EK; Department of Pharmacy, College of Pharmacy, Kyung Hee University, Seoul 02447, Korea.
Pharmaceuticals (Basel) ; 14(8)2021 Aug 09.
Article em En | MEDLINE | ID: mdl-34451882
ABSTRACT
This study aims to compare the prevalence and seriousness of adverse events (AEs) among sedatives used in critically ill patients or patients undergoing invasive procedures and to identify factors associated with serious AEs. Retrospective cross-sectional analysis of sedative-related AEs voluntarily reported to the Korea Adverse Event Reporting System from 2008 to 2017 was performed. All AEs were grouped using preferred terms and System Organ Classes per the World Health Organization-Adverse Reaction Terminology. Logistic regression was performed to identify factors associated with serious events. Among 95,188 AEs, including 3132 (3.3%) serious events, the most common etiologic sedative was fentanyl (58.8%), followed by pethidine (25.9%). Gastrointestinal disorders (54.2%) were the most frequent AEs. The most common serious AE was heart rate/rhythm disorders (33.1%). Serious AEs were significantly associated with male sex; pediatrics; etiologic sedative with etomidate at the highest risk, followed by dexmedetomidine, ketamine, and propofol; polypharmacy; combined sedative use; and concurrent use of corticosteroids, aspirin, neuromuscular blockers, and antihistamines (reporting odds ratio > 1, p < 0.001 for all). Sedative-induced AEs are most frequently reported with fentanyl, primarily manifesting as gastrointestinal disorders. Etomidate is associated with the highest risk of serious AEs, with the most common serious events being heart rate/rhythm disorders.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article